您的位置: 首页 > 农业专利 > 详情页

Cold-Adapted-Viral-Attenuation (CAVA) and novel attenuated Poliovirus strains
专利权人:
Janssen Vaccines & Prevention B.V.
发明人:
Sanders, Barbara Petronella,Custers, Jerome H.H.V.,Edo-Matas, Diana,Uil, Taco Gilles,Lewis, John Alfred
申请号:
AU2015276235
公开号:
AU2015276235A1
申请日:
2015.06.16
申请国别(地区):
AU
年份:
2016
代理人:
摘要:
A poliovirus (PV) strain was attenuated by a novel method of Cold-Adapted-Viral-Attenuation (CAVA). The resulting recombinant attenuated PV, CAVA-PV, shows wild- type replication at 30°C, but no substantial replication at 37°C. The inability to replicate at 37°C is defined by an inability to quantify virus during infection at this temperture by titration (infectious units), qPCR (viral RNA) or Electron Microscopy (visual signs of infection). CAVA-PV is genetically stable under production conditions and shows utility for use as the backbone to produce attenuated strains with the same antigenic profile as conventional vaccines by replacing the sequence coding for the capsid of CAVA-PV with sequences coding for capsids of different PV strains. Furthermore, mutations identified in CAVA-PV can be engineered into different, even wild-type and neurovirulent poliovirus background strains to obtain additional CAVA-PV strains.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充